Paliperidon Krka (Paliperidone)

Paliperidone, the active ingredient in Paliperidon Krka, is an atypical antipsychotic presented as a tablet for oral use. It is prescribed for the management of schizophrenia and related psychotic disorders in adults. GNH USA supplies Paliperidon Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Paliperidon Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Paliperidon Krka is an atypical antipsychotic that acts on dopamine and serotonin pathways to treat serious mental health conditions.

- Schizophrenia: helps reduce hallucinations, delusions and thought disorder. - Schizoaffective disorder: stabilises mood and psychotic symptoms. - Bipolar I disorder (maintenance): assists in preventing manic or depressive episodes when used as part of a broader treatment plan.

Paliperidone may cause a range of adverse reactions, most of which are dose‑dependent and reversible upon discontinuation.

Common Side Effects: - Akathisia (inner restlessness or fidget to the need to move). - Weight gain. - Dry mouth. - Constipation. - Drowsiness. - Increased prolactin levels.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome. - Tardive dyskinesia. - Seizures. - Orthostatic hypotension. - Severe hyperglycaemia. - Agranulocytosis. - Cardiac arrhythmias. - Elevated liver enzymes. - Suicide‑related thoughts and behaviour in adults and adolesc . - 

Paliperidone has several        a  a  ewline

t  ewline  ewline \n    ewline \n     ewline  ewline  \

The     ewline 

    \